Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Vor Biopharma Inc. VOR

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
97.29
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell 9 — — — — — 5 — — 1 — —
Insider Ownership
52.03%

Capital & Financial Ratios

Market Cap
1,300.00
Revenue
—
Net Income
0.00
Free Cash Flow
(94.61)
Net Debt
(123.50)
Current Ratio
10.69
Debt/Equity
0.21
P/E ratio
0.00
P/S ratio
0.00
P/B ratio
8.28
Past 5Y EPS Growth
(38.02%)
This Y EPS Growth
89.77%
Next Y EPS Growth
50.05%
Next 5Y EPS Growth
61.82%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2020 2021 2022 Q'23
Cash 48.54 207.47 230.25 160.10
Receivables — — — —
Inventory — — — —
Other 0.57 6.93 6.71 4.34
49.11 214.40 236.95 164.44
2020 2021 2022 Q'23
Payables 2.36 1.55 1.77 1.31
ST’ Debt 0.86 1.84 3.27 3.74
Other 6.98 6.77 8.08 10.34
10.21 10.15 13.12 15.39
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — — —
Cash Flow — — ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — — ‡‡‡‡‡

Revenue

Year
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (24.27) (24.10) (27.90) —
—
’22 (22.18) (17.48) (18.90) (18.35)
(85.14)
’21 (17.63) (15.44) (16.64) (16.87)
(69.14)
’20 (6.08) (8.52) (8.60) (13.48)
(36.29)
’19 — — — (5.61)
(9.85)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (24.27) (24.10) (27.90) —
—
’22 (22.18) (17.48) (18.90) (18.35)
(85.14)
’21 (17.63) (15.44) (16.64) (16.87)
(69.14)
’20 (6.08) (8.52) (8.60) (13.48)
(36.29)
’19 — — — (5.61)
(9.85)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (5.11) (1.16) — —
—
’25 (5.20) (251.20) (121.63) —
(70.50)
’24 (9.00) (8.20) (8.00) (8.80)
(34.00)
’23 (8.60) (9.00) (9.80) (7.80)
(35.00)
’22 (12.20) (11.60) (12.60) (10.60)
(46.60)
’21 (13.40) (10.00) (10.00) (9.80)
(42.00)
’20 (0.23) (0.24) (0.38) (0.48)
(4.61k)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1.3
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — — ‡‡‡‡‡ 69.60 32.40 12.60 2.62 — — —
Low Price
— — — — — ‡‡‡‡‡ 254.60 142.80 62.80 65.80 — — —
High Price
— — — — — — — — — — — — —
Employees
— — — — — — — — — — — — —
Revenue/Emp
— — — — — — — — — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% — — — — — —
Gross Margin
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (92.09) — — — — — —
EBT
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% — — — ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.96 — — — — — —
Depreciation
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (46.60) (35.00) (34.00) (70.50) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (43.08) 0.00 0.00 0.00 — — —
Cash Flow/Sh
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (43.08) 0.00 0.00 0.00 — — —
Free CF/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 126.81 0.00 0.00 0.00 — — —
Book Value/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.98 3.37 3.44 1.66 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — — — — — — — — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
— — — — — — — — — — ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — — — — — — — — — ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — — — — — — — — — ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
— — — — — — — — — — — — —
EV/FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (85.14) — — — ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (8.46) — — — ‡‡‡‡‡ — —
Capex
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (85.14) — — — ‡‡‡‡‡ — —
FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 223.83 — — — — — —
Working Cap'
— — ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ 38.91 — — — — — —
Total Debt
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (191.33) — — — — — —
Net Debt
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 250.61 — — — — — —
Sh' Equity
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% — — —
ROA
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% — — — — — —
ROIC
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (39.45%) 0.00% 0.00% 0.00% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Vor Biopharma Inc. (VOR), a clinical-stage biotech developing engineered hematopoietic stem cell therapies for AML and blood cancers, exemplifies the perils of speculative investing. Since its 2021 SPAC debut with a peak of $1,272, shares have cratered over 99% to around $13, driven by relentless cash burn, zero revenue, escalating losses (EPS from -$0.11 to -$47), and clinical delays amid a biotech funding winter. Balance sheet strains are evident: net cash has dwindled from -$302M peaks, book value eroded to zero, and free cash flow per share plunged to -$43, signaling a precarious runway without near-term sales.

Insider activity adds caution, with heavy selling (over $61M in proceeds from millions of shares in late 2025) and zero buys, coinciding with projections of a massive -$2.45B loss in 2025 before modest narrowing. Debt rose 116%, shares diluted, and ROE flipped deeply negative, underscoring dilution risks and inefficient capital use in a pre-revenue phase.

Analysts project wide uncertainty: -31% downside to 285% upside (mean 208%), hinging on VOR33 trial data in 2025-2026 amid tepid $1.26M revenue forecasts and ongoing negative cash flows. While breakthroughs could spark multi-fold gains, trial failures, further dilution, or macro headwinds pose existential threats—demanding ironclad risk tolerance for this high-wire act.

Read full commentary →

Vor Biopharma Inc. (VOR) Latest News

News by impact score

Fine-tune

8 Sep

4 , 7:00 AM
Vor Biopharma Inc. completes enrollment of global Phase 3 UPSTREAM MG trial and expands Telitacicept global franchise into ocular myasthenia gravis. Phase 3 enrollment completion plus new indication expansion advance Vor's clinical pipeline and market opportunities.

14 May

5 GlobeNewswire, 8:30 AM
Vor Bio announced publication of interim analysis from the TELIGAN China Phase 3 trial of telitacicept in IgA nephropathy in The New England Journal of Medicine. NEJM publication of Phase 3 interim analysis for telitacicept in IgA nephropathy marks a transformative clinical milestone for VOR's pipeline and prospects.

13 May

3 GlobeNewswire, 8:30 AM
Vor Biopharma Inc. (VOR) reported first quarter 2026 financial results and provided a corporate update. Quarterly financial results and corporate updates moderately influence financial performance and investor sentiment.

7 May

4 Zacks, 9:55 AM
Wall Street analysts predict Vor Biopharma (VOR) stock could rally 124.59% and provide trading strategies to capitalize on the upside. Analysts' 124.59% upside target signals strong buy sentiment likely to boost VOR stock price and investor interest significantly.

20 Apr

4 , 9:55 AM
Wall Street analysts expect Vor Biopharma (VOR) stock to rally 117%, driven by promising clinical data from its lead cell therapy candidate, trem-cel, targeting acute myeloid leukemia, with upside potential from partnerships and pipeline progress. Analyst consensus implies 117% upside based on strong clinical momentum, significantly lifting investor sentiment and potential market performance.

2 Apr

4 Zacks, 9:55 AM
Wall Street analysts predict a 107.82% upside for Vor Biopharma Inc. (VOR) stock. Analyst consensus targets 107.82% upside, likely driving significant investor sentiment and stock trajectory shifts.

3 Zacks, 12:00 PM
Analysts upgraded Vor Biopharma (VOR) to Buy rating, citing strong clinical progress, pipeline advancements, and undervalued potential driving positive outlook. Analyst upgrade to Buy moderately influences investor sentiment and stock performance amid biotech pipeline developments.

30 Mar

4 GlobeNewswire, 8:00 AM
Vor Biopharma Inc. (VOR) dosed the first patient in the global Phase 3 UPSTREAM SjD registrational trial of telitacicept for primary Sjögren’s disease. Dosing the first patient in a global Phase 3 registrational trial advances telitacicept toward potential approval in primary Sjögren’s disease, significantly impacting VOR's pipeline and market position.

3 GlobeNewswire, 8:01 AM
Vor Biopharma Inc. (VOR) reported fourth quarter and full-year 2025 financial results and provided a corporate update. Financial results and corporate updates moderately influence financial performance and investor sentiment without fundamentally altering trajectory.

27 Mar

4 GlobeNewswire, 8:00 AM
Vor Biopharma Inc. (VOR) announced a $75 million private placement financing with TCGX to support clinical trials and extend cash runway into 2026. $75 million private placement provides critical funding to advance VOR's cell therapy pipeline and extend runway through key milestones.

6 Jan

3 GlobeNewswire, 8:00 AM
Vor Biopharma Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference, a significant event for healthcare and biotech companies. The conference is known for showcasing innovations and strategic developments in the industry, providing Vor an opportunity to present its advancements and engage with investors and stakeholders. Participation in a major healthcare conference can enhance visibility and investor interest, potentially influencing market sentiment.

23 Dec

3 GlobeNewswire, 4:01 PM
Vor Biopharma Inc. has appointed Andrew Levin, M.D., Ph.D., from RA Capital, and Wouter Joustra from Forbion to its Board of Directors. This move aims to enhance the company's strategic direction and governance as it advances its pipeline of therapies for patients with cancer and other serious diseases. The appointments are expected to moderately influence the company's strategic direction and governance, potentially impacting its competitive positioning.

15 Dec

4 GlobeNewswire, 8:00 AM
Vor Biopharma Inc. announced a $150 million private placement to support its clinical development programs and general corporate purposes. The financing is expected to enhance the company's financial position and facilitate the advancement of its pipeline, which focuses on engineered cell therapies for cancer treatment. The placement is anticipated to close shortly, subject to customary closing conditions. The $150 million private placement is a significant strategic move that will bolster the company's financial resources and support its clinical development efforts.

12 Dec

4 Simply Wall St., 3:11 AM
Vor Biopharma Inc. (VOR) shares surged 45.6% following the successful Phase 3 trial results for Telitacicept, a treatment for autoimmune diseases. The positive outcome has garnered attention from JPMorgan, which has raised its outlook on the company. Analysts are now reassessing the bull case for VOR, considering the implications of the trial results on future growth and market positioning. The successful Phase 3 trial results and JPMorgan's endorsement are likely to significantly impact Vor Biopharma's future performance and investor sentiment.

10 Dec

4 Simply Wall St., 11:05 AM
Vor Biopharma Inc. (VOR) received positive Phase 3 data for its drug Telitacicept, which is expected to enhance its market position. Additionally, JPMorgan has initiated coverage with an optimistic outlook, further boosting investor sentiment. These developments suggest a promising trajectory for the company as it advances its product pipeline and strengthens its competitive stance in the biopharmaceutical sector. Positive Phase 3 data and favorable analyst coverage are likely to significantly impact Vor Biopharma's future performance and market perception.

9 Dec

3 Associated Press Finance, 10:30 AM
Vor Biopharma Inc. (VOR) has been identified as one of the most active stocks in the market, indicating heightened trading activity and interest among investors. This surge in activity may reflect investor sentiment regarding the company's recent developments or broader market trends affecting biotech stocks. Increased trading activity suggests moderate interest that could influence market sentiment and performance.

2 Dec

3 Simply Wall St., 9:08 AM
Vor Biopharma Inc. (VOR) is currently perceived as undervalued by 49%, prompting discussions about potential investment opportunities. Analysts are evaluating the company's financial health, product pipeline, and market positioning to determine if this undervaluation presents a strategic entry point for investors. The company's future performance may hinge on upcoming developments and market reactions. The 49% undervaluation indicates a moderately noticeable influence on investor sentiment and potential financial performance.

25 Nov

4 Zacks, 12:00 PM
Vor Biopharma Inc. (VOR) has been upgraded to a 'Buy' rating by analysts, reflecting positive sentiment regarding the company's future prospects. This upgrade is based on recent developments in their pipeline and market positioning, suggesting potential for growth and improved financial performance. Investors are encouraged to consider this upgrade as a signal of confidence in Vor Biopharma's strategic direction and product offerings. The upgrade to 'Buy' indicates significant positive sentiment and potential for improved market performance.

13 Nov

3 GlobeNewswire, 4:01 PM
Vor Biopharma Inc. reported its financial results for the third quarter of 2025, highlighting key metrics and developments in its corporate strategy. The company provided updates on its ongoing projects and future plans, emphasizing its commitment to advancing its pipeline and enhancing shareholder value. Financial performance indicators showed trends that may influence investor sentiment and market positioning. Financial results and corporate updates indicate moderate influence on future performance and market sentiment.

10 Nov

3 GlobeNewswire, 9:56 PM
Vor Biopharma Inc. has announced the pricing of a public offering of $100 million in common stock. The offering is expected to enhance the company's financial position and support its ongoing development initiatives. The shares are being offered at a price of $X per share, with the offering expected to close on a specified date, subject to customary closing conditions. Underwriters have a 30-day option to purchase additional shares to cover over-allotments. The public offering is likely to provide necessary capital for development but may not significantly alter the company's overall trajectory.

3 , 4:01 PM
Vor Biopharma Inc. has announced a proposed public offering of $100 million in common stock. The company intends to use the proceeds for general corporate purposes, which may include funding clinical trials and other operational expenses. The offering is expected to enhance the company's financial position and support its growth initiatives. The public offering could provide necessary funds for clinical trials and operations, impacting financial performance moderately.

8 Nov

3 GlobeNewswireTipRanksMT NewswiresMT Newswires, 11:45 AM
Telitacicept has successfully met its primary endpoint in a Phase 3 clinical study aimed at reducing proteinuria in patients with IgA nephropathy in China. This achievement marks a significant milestone in the development of treatments for this kidney disease, potentially paving the way for further advancements in patient care. The successful clinical trial results may enhance Vor Biopharma's competitive positioning in the biopharmaceutical market.

3 Nov

3 , 8:00 AM
Vor Biopharma Inc. has appointed Jeremy Sokolove, M.D. as its new Chief Medical Officer. Dr. Sokolove brings extensive experience in clinical development and has previously held leadership roles in various biopharmaceutical companies. His appointment is expected to enhance Vor Biopharma's strategic direction and clinical initiatives as the company focuses on advancing its pipeline of therapies. The appointment of a new Chief Medical Officer may influence the company's clinical strategy and product development.

29 Oct

4 GlobeNewswire, 11:01 AM
Telitacicept has shown sustained efficacy and a favorable safety profile in a 48-week Phase 3 open-label extension study for generalized myasthenia gravis in China. The results indicate promising long-term benefits for patients, potentially enhancing treatment options in this area. The positive Phase 3 results could significantly influence Vor Biopharma's market position and investor sentiment regarding its therapeutic offerings.

22 Oct

4 GlobeNewswire, 4:30 PM
Vor Biopharma Inc. will host a webcast to present late-breaking Phase 3 data on telitacicept for treating primary Sjögren’s disease in China. This event aims to share significant findings that could impact the company's future strategies and market positioning. The presentation of late-breaking Phase 3 data could significantly influence Vor Biopharma's market performance and strategic direction.

17 Oct

4 TipRanksClinical Trials ArenaTipRanksBioPharma DiveMT NewswiresMT NewswiresMT NewswiresMT Newswires, 8:15 AM
Vor Biopharma Inc. announced that its Phase 3 study on telitacicept for systemic lupus erythematosus (SLE) successfully met its primary endpoint. This achievement marks a significant milestone in the development of telitacicept as a potential treatment for SLE, a chronic autoimmune disease. The positive results from the study may enhance Vor Biopharma's position in the market and pave the way for further advancements in their therapeutic offerings. Meeting the primary endpoint in a Phase 3 study is a significant milestone that could greatly influence Vor Biopharma's market position and future performance.

4 GlobeNewswire, 8:00 AM
Vor Biopharma Inc. announced a late-breaking oral presentation regarding its Phase 3 clinical study on IgA Nephropathy in China at the American Society of Nephrology’s Kidney Week 2025. This presentation highlights the company's ongoing research and development efforts in addressing this kidney disease, potentially impacting treatment options and patient outcomes. The presentation of significant clinical study results could influence investor sentiment and the company's strategic positioning in the nephrology market.

16 Oct

4 GlobeNewswire, 8:00 AM
Vor Biopharma Inc. announced the publication of a Phase 3 study of Telitacicept for treating systemic lupus erythematosus in China, which has been featured in The New England Journal of Medicine. The study's results are expected to contribute to the understanding and treatment of this autoimmune disease, potentially enhancing Vor Biopharma's position in the biopharmaceutical market. The publication of significant clinical trial results in a prestigious journal is likely to enhance investor sentiment and support future product development.

14 Oct

4 GlobeNewswirePharmaceutical TechnologyBioPharma DiveClinical Trials ArenaClinical Trials Arena, 8:00 AM
Telitacicept has shown a clinically meaningful and statistically significant impact on the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) compared to placebo in a Phase 3 trial for Primary Sjögren’s Disease conducted in China. The results were presented as a late-breaking abstract at ACR 2025, highlighting the potential of telitacicept as a treatment option for this condition. The positive Phase 3 trial results for telitacicept could significantly enhance Vor Biopharma's market position and investor sentiment.

29 Sep

4 GlobeNewswire, 7:00 AM
Vor Biopharma Inc. announced a late-breaking poster presentation of its Phase 3 clinical study on Primary Sjögren’s Disease at the ACR Convergence 2025. This presentation highlights the company's ongoing research and development efforts in addressing this autoimmune condition, potentially showcasing new data that could influence treatment approaches and market interest. The presentation of Phase 3 clinical study results could significantly impact Vor Biopharma's market position and investor sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us